Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
暂无分享,去创建一个
Mark Crowther | J. Hirsh | E. Hylek | G. Palareti | M. Crowther | J. Ansell | Jack Hirsh | Gualtiero Palareti | Jack Ansell | Elaine Hylek | Alan Jacobson | A. Jacobson
[1] C. Frei,et al. Dietary supplement use among anticoagulation clinic patients , 2007, Journal of thrombosis and haemostasis : JTH.
[2] F. Kamali,et al. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. , 2007, Blood.
[3] C. Moore,et al. Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios , 2007, Journal of Thrombosis and Thrombolysis.
[4] Gregory W Albers,et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. , 2007, Archives of internal medicine.
[5] Alan D. Woolf,et al. Long-acting anticoagulant rodenticide poisoning: An evidence-based consensus guideline for out-of-hospital management , 2007, Clinical toxicology.
[6] I. Shapira,et al. The interval between prothrombin time tests and the quality of oral anticoagulants treatment in patients with chronic atrial fibrillation. , 2007, Thrombosis research.
[7] Marlene R. Miller,et al. Prevention of thromboembolism in atrial fibrillation , 2007, Journal of General Internal Medicine.
[8] S. Mayer,et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. , 2007, Mayo Clinic proceedings.
[9] Samuel Wann,et al. [Guidelines for the management of patients with atrial fibrillation. Executive summary]. , 2006, Revista espanola de cardiologia.
[10] Russ Altman,et al. Pharmacogenomics: Challenges and Opportunities , 2006, Annals of Internal Medicine.
[11] S. Kitchen,et al. Point-of-care International Normalised Ratios: UK NEQAS experience demonstrates necessity for proficiency testing of three different monitors , 2006, Thrombosis and Haemostasis.
[12] J. Ingerslev,et al. A direct thrombin inhibitor studied by dynamic whole blood clot formation , 2006, Thrombosis and Haemostasis.
[13] G. Guyatt,et al. Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study , 2006, The Lancet Neurology.
[14] Samuel Wann,et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ , 2006, European heart journal.
[15] D. Singer,et al. Age and the Risk of Warfarin‐Associated Hemorrhage: The Anticoagulation and Risk Factors In Atrial Fibrillation Study , 2006, Journal of the American Geriatrics Society.
[16] T. Albertson,et al. Reversal of Elevated International Normalized Ratios and Bleeding with Low‐Dose Recombinant Activated Factor VII in Patients Receiving Warfarin , 2006, Pharmacotherapy.
[17] E. Nutescu,et al. Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic , 2006, Thrombosis and Haemostasis.
[18] H. Cheng. IS AGE A RISK FACTOR FOR WARFARIN‐RELATED MAJOR BLEEDS IN ELDERLY PATIENTS WITH ATRIAL FIBRILLATION? , 2006, Journal of the American Geriatrics Society.
[19] SHOULD WE PRESCRIBE VITAMIN D AND CALCIUM TO OLD PERSONS TO PREVENT FALLS AND FRACTURES? , 2006, Journal of the American Geriatrics Society.
[20] L. Lynd,et al. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy , 2006, Canadian Medical Association Journal.
[21] M. Pfeffer,et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.
[22] F. Dentali,et al. Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency , 2006, Annals of Internal Medicine.
[23] A. Forster,et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. , 2006, Chest.
[24] Yi-ping Fu,et al. CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[25] V. Dolžan,et al. The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement , 2006, Thrombosis and Haemostasis.
[26] G. Biondi-Zoccai,et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. , 2006, European heart journal.
[27] E. Hylek,et al. The risk of hemorrhage among patients with warfarin-associated coagulopathy. , 2006, Journal of the American College of Cardiology.
[28] R. Perera,et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis , 2006, The Lancet.
[29] C. Eby,et al. Population variation in VKORC1 haplotype structure , 2006, Journal of thrombosis and haemostasis : JTH.
[30] H. Halkin,et al. Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin , 2006, Thrombosis and Haemostasis.
[31] J. Peters,et al. Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin , 2004, Heart.
[32] V. Dolžan,et al. A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) ina patient on warfarin therapy , 2006, Thrombosis and Haemostasis.
[33] S. Scialla,et al. Therapeutic management of a patient with a unique factor IX sensitivity to warfarin. , 2006, Clinical advances in hematology & oncology : H&O.
[34] L. Drouet,et al. Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study. , 2006, Haematologica.
[35] Anders Odén,et al. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. , 2006, Thrombosis research.
[36] M. Meade,et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. , 2005, Journal of critical care.
[37] L. Morgan,et al. Low‐Dose Vitamin K to Augment Anticoagulation Control , 2005, Pharmacotherapy.
[38] G. Samsa,et al. Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies , 2004, Thrombosis and Haemostasis.
[39] D. Fitzmaurice,et al. Self management of oral anticoagulation: randomised trial , 2005, BMJ : British Medical Journal.
[40] D. Fitzmaurice,et al. An evidence‐based review and guidelines for patient self‐testing and management of oral anticoagulation , 2005, British journal of haematology.
[41] T. Wienker,et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation , 2005, Thrombosis and Haemostasis.
[42] Peter Wood,et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.
[43] C. Verstuyft,et al. Vitamin K epoxide reductase (VKORC1) genetic polymorphism is associated to oral anticoagulant overdose , 2005, Thrombosis and Haemostasis.
[44] Jeroen J. Bax,et al. Risk stratification of patients with classic angina pectoris and no history of coronary artery disease by dobutamine stress echocardiography. , 2005, Journal of the American College of Cardiology.
[45] W. Ageno,et al. A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. , 2005, Journal of the American College of Cardiology.
[46] M. Kovacs,et al. Fondaparinux: A potential new therapy for HIT , 2005, Hematology.
[47] D. Stafford. The vitamin K cycle , 2005, Journal of thrombosis and haemostasis : JTH.
[48] S. Lydersen,et al. Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation , 2005, Journal of internal medicine.
[49] D. Horstkotte,et al. Drug Insight: an overview of current anticoagulation therapy after heart valve replacement , 2005, Nature Clinical Practice Cardiovascular Medicine.
[50] M. Caldwell,et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. , 2005, Clinical medicine & research.
[51] E. E. van der Wall,et al. Risks of oral anticoagulant therapy with increasing age. , 2005, Archives of internal medicine.
[52] B. Lewis,et al. Transitioning from Argatroban to Warfarin Therapy in Patients with Heparin-induced Thrombocytopenia , 2005, Clinical and applied thrombosis/hemostasis.
[53] D. Anderson,et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.
[55] J. Kovačević-Metelko,et al. Successful reversal of anticoagulant effect of superwarfarin poisoning with recombinant activated factor VII , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[56] E. Hylek,et al. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. , 2005, Chest.
[57] G. Tenderich,et al. Low-dose international normalized ratio self-management: a promising tool to achieve low complication rates after mechanical heart valve replacement. , 2005, The Annals of thoracic surgery.
[58] P. Lavori,et al. The Impact of Patient Self-Testing of Prothrombin Time for Managing Anticoagulation: Rationale and Design of VA Cooperative Study #481—The Home INR Study (THINRS) , 2005, Journal of Thrombosis and Thrombolysis.
[59] Mark Crowther,et al. Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.
[60] M. Franchini,et al. Recombinant factor VIIa. An update on its clinical use. , 2005, Thrombosis and haemostasis.
[61] M. Rieder,et al. CYP2C9 Haplotype Structure in European American Warfarin Patients and Association with Clinical Outcomes , 2005, Clinical pharmacology and therapeutics.
[62] B. Cosmi,et al. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long‐term recurrence , 2005, Journal of thrombosis and haemostasis : JTH.
[63] T. Barbui,et al. A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) 1 , 2005, Journal of thrombosis and haemostasis : JTH.
[64] D. Witt,et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. , 2005, Chest.
[65] F. Kamali,et al. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation , 2005, Thrombosis and Haemostasis.
[66] G. Marchetti,et al. Risks factors for highly unstable response to oral anticoagulation: a case‐control study , 2005, British journal of haematology.
[67] Vera Ignjatovic,et al. Reduced Bone Density in Children on Long-Term Warfarin , 2005, Pediatric Research.
[68] R. Day,et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. , 2005, British journal of clinical pharmacology.
[69] R. Becker. The Importance of Factor Xa Regulatory Pathways in Vascular Thromboresistance: Focus on Protein Z , 2005, Journal of Thrombosis and Thrombolysis.
[70] S. Kasner,et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. , 2005, The New England journal of medicine.
[71] H. Völler,et al. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. , 2005, International journal of cardiology.
[72] M. Margaglione,et al. Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation , 2005, Thrombosis and Haemostasis.
[73] Howard L McLeod,et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype , 2005, Thrombosis and Haemostasis.
[74] D. J. Glatz,et al. Self-Management of oral Anticoagulation in nonvalvular Atrial Fibrillation (SMAAF study) , 2005, Zeitschrift für Kardiologie.
[75] C. Francis,et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. , 2005, JAMA.
[76] Palle Petersen,et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. , 2005, JAMA.
[77] M. Verny,et al. Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. , 2005, American Journal of Medicine.
[78] E. M. Cott,et al. Use of the Chromogenic Factor X Assay to Predict the International Normalized Ratio in Patients Transitioning from Argatroban to Warfarin , 2005, Pharmacotherapy.
[79] S. Hoerstrup,et al. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra®) on human osteoblasts in vitro , 2005, The British journal of surgery.
[80] J. Bartholomew. Transition to an oral anticoagulant in patients with heparin-induced thrombocytopenia. , 2005, Chest.
[81] D. Greenblatt,et al. Interaction of Warfarin With Drugs, Natural Substances, and Foods , 2005, Journal of clinical pharmacology.
[82] J. Tijssen,et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. a retrospective study of 2300 consecutive patients with venous thromboembolism , 2005, British journal of haematology.
[83] A. Laupacis,et al. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. , 2005, Archives of internal medicine.
[84] E. Ernst,et al. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. , 2005, International journal of cardiology.
[85] M. Margaglione,et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.
[86] X. Bonfill,et al. Comparing Self-Management of Oral Anticoagulant Therapy with Clinic Management , 2005, Annals of Internal Medicine.
[87] M. Shearer,et al. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1 , 2004, Thrombosis and Haemostasis.
[88] N. Samuels. Herbal remedies and anticoagulant therapy , 2004, Thrombosis and Haemostasis.
[89] R. Bergemann,et al. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study. , 2005, Chest.
[90] H. Naritomi,et al. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. , 2005, Thrombosis research.
[91] J. Kelton,et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. , 2005, Blood.
[92] H. Halkin,et al. Over-the-counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1-depleted patients , 2004, Thrombosis and Haemostasis.
[93] M. Shearer,et al. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. , 2004, Blood.
[94] T. Christensen. Self-Management of Oral Anticoagulant Therapy: A Review , 2004, Journal of Thrombosis and Thrombolysis.
[95] A. Abdelhafiz,et al. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. , 2004, Clinical therapeutics.
[96] A. Fung,et al. A randomized trial of patient self-managed versus physician-managed oral anticoagulation. , 2004, The Canadian journal of cardiology.
[97] S. Pauker,et al. Antithrombotic therapy in valvular heart disease--native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[98] J. Hirsh,et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[99] E. Hylek. Paracetamol (acetaminophen) and warfarin interaction: unraveling the pivotal role of the vitamin K cycle. , 2004, Thrombosis and haemostasis.
[100] F. Kamali,et al. The value of education and self‐monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation , 2004, British journal of haematology.
[101] L. Vervoort,et al. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle , 2004, Thrombosis and Haemostasis.
[102] T. Karrison,et al. Brief Communication: American Ginseng Reduces Warfarin's Effect in Healthy Patients , 2004, Annals of Internal Medicine.
[103] M. Bullano,et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. , 2004, Clinical therapeutics.
[104] I. Kaczmarczyk-Sedlak,et al. Effects of enoxaparin on histomorphometric parameters of bones in rats. , 2004, Polish journal of pharmacology.
[105] Samuel Z Goldhaber,et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms , 2004, Thrombosis and Haemostasis.
[106] H. Echizen,et al. CYP2C9 and Oral Anticoagulation Therapy with Acenocoumarol and Warfarin: Similarities yet Differences , 2004, Clinical pharmacology and therapeutics.
[107] F. V. D. van der Meer,et al. Patient self‐management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life , 2004, Journal of thrombosis and haemostasis : JTH.
[108] Andreas Fregin,et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.
[109] A. Khvorova,et al. Identification of the gene for vitamin K epoxide reductase , 2004, Nature.
[110] M. Gent,et al. Comparison of Low-Intensity Warfarin Therapy With Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism , 2004 .
[111] J. Bartholomew,et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. , 2004, Archives of internal medicine.
[112] A. Berghold,et al. Systematic review of studies of self-management of oral anticoagulation , 2004, Thrombosis and Haemostasis.
[113] Howard L McLeod,et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin , 2003, Thrombosis and Haemostasis.
[114] J. Speckman,et al. Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range , 2003, Journal of Thrombosis and Thrombolysis.
[115] A. Wittkowsky. Drug Interactions Update: Drugs, Herbs, and Oral Anticoagulation , 2001, Journal of Thrombosis and Thrombolysis.
[116] M. Brophy,et al. Anaphylactoid Reactions to Vitamin K , 2001, Journal of Thrombosis and Thrombolysis.
[117] David B. Matchar,et al. Relationship Between Test Frequency and Outcomes of Anticoagulation: A Literature Review and Commentary with Implications for the Design of Randomized Trials of Patient Self-Management , 2000, Journal of Thrombosis and Thrombolysis.
[118] J. Gurwitz,et al. Long-Term Anticoagulation Therapy for Atrial Fibrillation in Elderly Patients: Efficacy, Risk, and Current Patterns of Use , 1999, Journal of Thrombosis and Thrombolysis.
[119] M. Crowther,et al. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10. , 2004, Thrombosis research.
[120] A. Hofman,et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon , 2004, Thrombosis and Haemostasis.
[121] D. Horstkotte,et al. Optimal Frequency of Patient Monitoring and Intensity of Oral Anticoagulation Therapy in Valvular Heart Disease , 2004, Journal of Thrombosis and Thrombolysis.
[122] J. Ansell,et al. Anticoagulation Management as a Risk Factor for Adverse Events: Grounds for Improvement , 2004, Journal of Thrombosis and Thrombolysis.
[123] S. Iliceto,et al. A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment. , 2003, American journal of clinical pathology.
[124] F. Rosendaal,et al. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. , 2003, Archives of internal medicine.
[125] S. Olsson,et al. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial , 2003, The Lancet.
[126] J. Douketis,et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. , 2003, The New England journal of medicine.
[127] Yuchiao Chang,et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. , 2003, The New England journal of medicine.
[128] D. Anderson,et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[129] A. Disch,et al. Effects of Fondaparinux Compared with Dalteparin, Enoxaparin and Unfractionated Heparin on Human Osteoblasts , 2003, Calcified Tissue International.
[130] M. Greaves,et al. INRs and point of care testing , 2003, BMJ : British Medical Journal.
[131] J. Jespersen,et al. Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods , 2003, BMJ : British Medical Journal.
[132] J. C. Sørensen,et al. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[133] S. Chow,et al. Correlation of Antifactor Xa Concentrations with Renal Function in Patients on Enoxaparin , 2003, Journal of clinical pharmacology.
[134] D. Anderson,et al. Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together with Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism , 2003, Annals of Internal Medicine.
[135] L. Norgren,et al. Enoxaparin effect depends on body‐weight and current doses may be inadequate in obese patients , 2003, The British journal of surgery.
[136] A. Turpie,et al. Perioperative management of patients receiving oral anticoagulants: a systematic review. , 2003, Archives of internal medicine.
[137] P. Ridker,et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.
[138] H. Ng,et al. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin , 2003, Annals of Hematology.
[139] A. Torbicki,et al. Changes in Bone Density during Long-Term Administration of Low-Molecular-Weight Heparins or Acenocoumarol for Secondary Prophylaxis of Venous Thromboembolism , 2003, Pathophysiology of Haemostasis and Thrombosis.
[140] J. Jespersen,et al. European Concerted Action on Anticoagulation (ECAA). An assessment of lyophilised plasmas for ISI calibration of CoaguChek and TAS whole blood prothrombin time monitors , 2003, Journal of clinical pathology.
[141] D. Fitzmaurice,et al. A systematic review of outcome measures reported for the therapeutic effectiveness of oral anticoagulation , 2003, Journal of clinical pathology.
[142] E. Antman,et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment : Analysis from the ESSENCE and TIMI 11 B studies , 2003 .
[143] M. Lapeyre-Mestre,et al. Utilisation and Safety of Low Molecular Weight Heparins , 2003, Drug safety.
[144] J. Fontcuberta,et al. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. , 2003, Haematologica.
[145] C. Kessler,et al. Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate , 2002, Annals of Internal Medicine.
[146] Carl van Walraven,et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. , 2002, JAMA.
[147] R. Peters,et al. Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers , 2002, Circulation.
[148] D. Grobbee,et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2) study: a randomized controlled trial , 2002 .
[149] D. Fitzmaurice,et al. A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management , 2002, Journal of clinical pathology.
[150] H. Arnesen,et al. Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.
[151] J. Douketis,et al. Oral Vitamin K Lowers the International Normalized Ratio More Rapidly Than Subcutaneous Vitamin K in the Treatment of Warfarin-Associated Coagulopathy , 2002, Annals of Internal Medicine.
[152] D. Grobbee,et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial , 2002, The Lancet.
[153] H. Kock,et al. Osteoblast Growth Inhibition by Unfractionated Heparin and by Low Molecular Weight Heparins: An in-vitro Investigation , 2002, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[154] G. Samsa,et al. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. , 2002, The American journal of medicine.
[155] F. Rosendaal,et al. Therapeutic quality control of oral anticoagulant therapy comparing the short‐acting acenocoumarol and the long‐acting phenprocoumon , 2002, British journal of haematology.
[156] K. Winther,et al. Effect of Coenzyme Q10 and Ginkgo biloba on Warfarin Dosage in Stable, Long-term Warfarin Treated Outpatients. A Randomised, Double Blind, Placebo-crossover Trial , 2002, Thrombosis and Haemostasis.
[157] F. Horber,et al. Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis. , 2002, Thrombosis research.
[158] E. Antman,et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. , 2002, American heart journal.
[159] P. Thodiyil,et al. Variation in Relative Risk of Venous Thromboembolism in Different Cancers , 2002, Thrombosis and Haemostasis.
[160] C. Vergnes,et al. Absence of Placental Transfer of Pentasaccharide (Fondaparinux, Arixtra®) in the Dually Perfused Human Cotyledon in vitro , 2002, Thrombosis and Haemostasis.
[161] David L Veenstra,et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.
[162] T. Wakefield. Managing oral anticoagulation therapy: Clinical and operational guidelines , 2002 .
[163] Hui-hua Li,et al. Better anticoagulation control improves survival after valve replacement. , 2002, The Journal of thoracic and cardiovascular surgery.
[164] S. Sonnad,et al. Comparison of narrow versus standard target INR ranges , 2002 .
[165] D. Heaton,et al. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis , 2002, Internal medicine journal.
[166] H. Ehrlich,et al. Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[167] J. Jespersen,et al. European Concerted Action on Anticoagulation (ECAA): multicentre international sensitivity index calibration of two types of point‐of‐care prothrombin time monitor systems , 2002, British journal of haematology.
[168] M. Ezekowitz,et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial Comparing Combined Warfarin and Aspirin With Aspirin Alone in Survivors of Acute Myocardial Infarction: Primary Results of the CHAMP Study , 2002, Circulation.
[169] V. Hiilesmaa,et al. Postpartum Bone Mineral Density in Women Treated for Thromboprophylaxis with Unfractionated Heparin or LMW Heparin , 2002, Thrombosis and Haemostasis.
[170] D. Scholten,et al. A Comparison of Two Different Prophylactic Dose Regimens of Low Molecular Weight Heparin in Bariatric Surgery , 2002, Obesity surgery.
[171] J. Necciari,et al. The Pharmacokinetics of Fondaparinux Sodium in Healthy Volunteers , 2002, Clinical pharmacokinetics.
[172] L. Delbressine,et al. Fondaparinux Sodium Is Not Metabolised in Mammalian Liver Fractions and Does Not Inhibit Cytochrome P450-Mediated Metabolism of Concomitant Drugs , 2002, Clinical pharmacokinetics.
[173] R. Bergemann,et al. Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA (GELIA 5) , 2001 .
[174] R. Bergemann,et al. Economic analysis of bleeding and thromboembolic sequelae after heart valve replacement (GELIA 7) , 2001 .
[175] H. O'kane,et al. Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients. , 2001, The Annals of thoracic surgery.
[176] T. Warkentin. Venous Limb Gangrene during Warfarin Treatment of Cancer-Associated Deep Venous Thrombosis , 2001, Annals of Internal Medicine.
[177] T. Baglin,et al. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over‐anticoagulation with warfarin , 2001, British journal of haematology.
[178] R. Tait,et al. Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. , 2001, Archives of internal medicine.
[179] S. Skates,et al. Clinical Predictors of Prolonged Delay in Return of the International Normalized Ratio to within the Therapeutic Range after Excessive Anticoagulation with Warfarin , 2001, Annals of Internal Medicine.
[180] H. Halkin,et al. Interindividual variability in sensitivity to warfarin‐Nature or nurture? , 2001, Clinical pharmacology and therapeutics.
[181] W. Ageno,et al. Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement. , 2001, The American journal of cardiology.
[182] R. Körfer,et al. International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous? , 2001, The Annals of thoracic surgery.
[183] C. Doetkott,et al. Clinical impact of interlaboratory variation in international normalized ratio determinations. , 2001, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[184] S. Yusuf,et al. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina , 2001 .
[185] J. Venitz,et al. The Pharmacokinetics of Subcutaneous Enoxaparin in End‐Stage Renal Disease , 2001, Pharmacotherapy.
[186] J. Hixson-Wallace,et al. Effect of Regimen Complexity on Patient Satisfaction and Compliance With Warfarin Therapy , 2001, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[187] H. Echizen,et al. Pharmacogenetics of Warfarin Elimination and its Clinical Implications , 2001, Clinical pharmacokinetics.
[188] A. Multicenter,et al. Point-of-care prothrombin time measurement for professional and patient self-testing use. A multicenter clinical experience. Oral Anticoagulation Monitoring Study Group. , 2001, American journal of clinical pathology.
[189] M. Moia,et al. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). , 2001, Haematologica.
[190] F. Depasse,et al. Anti-Xa monitoring: inter-assay variability. , 2000, Thrombosis and haemostasis.
[191] R. Robson. The use of bivalirudin in patients with renal impairment. , 2000, The Journal of invasive cardiology.
[192] M. Moia,et al. Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: a prospective multicenter study. , 2000, Thrombosis research.
[193] R. Beyth,et al. A Multicomponent Intervention To Prevent Major Bleeding Complications in Older Patients Receiving Warfarin , 2000, Annals of Internal Medicine.
[194] J. Douketis,et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial , 2000, The Lancet.
[195] P. Kamath,et al. Normalizing the prothrombin time , 2000 .
[196] O. Chazouilleres,et al. Normalizing the prothrombin time , 2000, Hepatology.
[197] A. M. H. P. V. D. Besselar. A comparison of INRs determined with a whole blood prothrombin time device and two international reference preparations for thromboplastin. , 2000 .
[198] M. O’Connell,et al. Evaluation of Warfarin Initiation Regimens in Elderly Inpatients , 2000, Pharmacotherapy.
[199] M. Prins,et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison , 2000, The Lancet.
[200] J. F. Barnes,et al. Enoxaparin and Bleeding Complications: A Review in Patients with and without Renal Insufficiency , 2000, Pharmacotherapy.
[201] E. Mcmahon,et al. Falsely elevated INRs in warfarin-treated patients with the lupus anticoagulant. , 2000, WMJ : official publication of the State Medical Society of Wisconsin.
[202] W. Ageno,et al. A Computer Generated Induction System for Hospitalized Patients Starting on Oral Anticoagulant Therapy , 2000, Thrombosis and Haemostasis.
[203] A. Bernardo,et al. Clinical outcome of self-management of oral anticoagulation in patients with atrial fibrillation or deep vein thrombosis. , 2000, Thrombosis research.
[204] J. T. Owings,et al. A Comparison of Point-of-Care Instruments Designed for Monitoring Oral Anticoagulation with Standard Laboratory Methods , 2000, Thrombosis and Haemostasis.
[205] A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. , 2000, Thrombosis and haemostasis.
[206] D. Witter,et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. , 2000, Archives of internal medicine.
[207] S. Swan,et al. The Pharmacokinetics and Pharmacodynamics of Argatroban: Effects of Age, Gender, and Hepatic or Renal Dysfunction , 2000, Pharmacotherapy.
[208] J. Hirsh,et al. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. , 2000, Archives of internal medicine.
[209] A. Van den Besselaar,et al. A comparison of INRs determined with a whole blood prothrombin time device and two international reference preparations for thromboplastin. , 2000, Thrombosis and haemostasis.
[210] E. Berntorp. Recombinant FVIIa in the Treatment of Warfarin Bleeding , 2000, Seminars in thrombosis and hemostasis.
[211] R. Kumar,et al. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. , 1999, Archives of internal medicine.
[212] A. Wittkowsky,et al. Influence of Warfarin Regimen Type on Clinical and Monitoring Outcomes in Stable Patients in an Anticoagulation Management Service , 1999, Pharmacotherapy.
[213] Sonia S Anand,et al. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. , 1999, JAMA.
[214] J. Knottnerus,et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin , 1999, BMJ.
[215] O. Benavente,et al. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.
[216] M. Prins,et al. Comparison of Three Methods to Assess Therapeutic Quality Control of Treatment with Vitamin K Antagonists , 1999, Thrombosis and Haemostasis.
[217] S. Kitchen,et al. Anti Xa Monitoring during Treatment with Low Molecular Weight Heparin or Danaparoid: Inter-assay Variability , 1999, Thrombosis and Haemostasis.
[218] W. Feinberg,et al. Clinically significant differences in the International Normalized Ratio measured with reagents of different sensitivities. SPAF Investigators. Stroke Prevention in Atrial Fibrillation. , 1999, Blood Coagulation and Fibrinolysis.
[219] Y. Byun,et al. Low molecular weight protamine: a potential nontoxic heparin antagonist. , 1999, Thrombosis research.
[220] P. Mannucci,et al. Genetic control of anticoagulation , 1999, The Lancet.
[221] G. Aithal,et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.
[222] P. Sawicki,et al. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. , 1999, JAMA.
[223] J. Hirsh,et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. , 1999, Archives of internal medicine.
[224] J. Harenberg,et al. The Effect of Self-Monitoring the INR on Quality of Anticoagulation and Quality of Life , 1999, Seminars in thrombosis and hemostasis.
[225] K. Haustein. Pharmacokinetic and Pharmacodynamic Properties of Oral Anticoagulants, Especially Phenprocoumon , 1999, Seminars in thrombosis and hemostasis.
[226] S. Shinjo,et al. Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine. , 1999, Seminars in thrombosis and hemostasis.
[227] D. Perry,et al. Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal. , 1998, Clinical and laboratory haematology.
[228] J. Jespersen,et al. Multicentre randomised study of computerised anticoagulant dosage , 1998, The Lancet.
[229] J. Boissel,et al. The effect of recombinant factor VIIa (NovoSeven™) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0 , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[230] H. Bussey,et al. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. , 1998, Archives of internal medicine.
[231] J. Douketis,et al. Accuracy of a portable International Normalization Ratio monitor in outpatients receiving long-term oral anticoagulant therapy: comparison with a laboratory reference standard using clinically relevant criteria for agreement. , 1998, Thrombosis research.
[232] R. White,et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy. , 1998, Archives of pathology & laboratory medicine.
[233] W. Ageno,et al. A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. , 1998, Thrombosis research.
[234] M G Amato,et al. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. , 1998, Archives of internal medicine.
[235] R. Beyth,et al. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. , 1998, The American journal of medicine.
[236] G. Boysen,et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. , 1998, Archives of internal medicine.
[237] G. Reber,et al. Control of Oral Anticoagulation in Patients with the Antiphospholipid Syndrome – Influence of the Lupus Anticoagulant on International Normalized Ratio , 1998, Thrombosis and Haemostasis.
[238] J. Necciari,et al. Aging and Venous Thromboembolism Influence the Pharmacodynamics of the Anti-Factor Xa and Anti-thrombin Activities of a Low Molecular Weight Heparin (Nadroparin) , 1998, Thrombosis and Haemostasis.
[239] R. Marcus,et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies , 1998, British journal of haematology.
[240] J. Miners,et al. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.
[241] A. Manoharan. Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants , 1998, Annals of Internal Medicine.
[242] D. Malone,et al. Evaluation of excessive anticoagulation in a group model health maintenance organization. , 1998, Archives of internal medicine.
[243] Heather L. Heiman,et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation , 1998 .
[244] W. Bell. Acetaminophen and Warfarin: Undesirable Synergy , 1998 .
[245] T. Meade,et al. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk , 1998, The Lancet.
[246] P. Cachia,et al. Accuracy and precision of the TAS analyser for near-patient INR testing by non-pathology staff in the community. , 1998, Journal of clinical pathology.
[247] J Jespersen,et al. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. , 1998, Lancet.
[248] J. Hirsh,et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. , 1998, Chest.
[249] J. Dahlerup,et al. Major haemorrhagic complications during oral anticoagulant therapy in a Danish Population‐based cohort , 1997, Journal of internal medicine.
[250] M. Moia,et al. Thrombotic Events during Oral Anticoagulant Treatment: Results of the Inception-cohort, Prospective, Collaborative ISCOAT Study , 1997, Thrombosis and Haemostasis.
[251] F. Verheugt,et al. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin , 1997, Annals of neurology.
[252] J. Kelton,et al. The Pathogenesis of Venous Limb Gangrene Associated with Heparin-Induced Thrombocytopenia , 1997, Annals of Internal Medicine.
[253] S. Kitchen,et al. Monitoring oral anticoagulant treatment with the TAS near-patient test system: comparison with conventional thromboplastins. , 1997, Journal of clinical pathology.
[254] H. Bussey,et al. A Review of Enzyme Induction of Warfarin Metabolism with Recommendations for Patient Management , 1997, Pharmacotherapy.
[255] P. Petersen,et al. 1-49-02 Fixed low-dose warfarin alone or combined with aspirin and aspirin alone versus adjusted-dose warfarin for stroke prevention in atrial fibrillation. Second copenhagen atrial fibrillation, aspirin and anticoagulation study (AFASAK 2) , 1997, Journal of the Neurological Sciences.
[256] I. Mackie,et al. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti‐phospholipid syndrome , 1997, British journal of haematology.
[257] Coumadin Aspirin Reinfarction Study Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction , 1997, The Lancet.
[258] P. Mannucci,et al. Determination of the International Sensitivity Index of a New Near-Patient Testing Device to Monitor Oral Anticoagulant Therapy , 1997, Thrombosis and Haemostasis.
[259] H. Roberts,et al. Warfarin and Heparin-Induced Skin Necrosis and the Purple Toe Syndrome: Infrequent Complications of Anticoagulant Treatment , 1997, Thrombosis and Haemostasis.
[260] J. Oldenburg,et al. Missense mutations at ALA‐10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy , 1997, British journal of haematology.
[261] P. Rolan,et al. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin , 1997, Clinical pharmacology and therapeutics.
[262] S. Rapaport,et al. Correction of Excessive Anticoagulation with Low-Dose Oral Vitamin K1 , 1997, Annals of Internal Medicine.
[263] J. Hirsh,et al. Management of anticoagulation before and after elective surgery. , 1997, The New England journal of medicine.
[264] J. Ansell,et al. Consensus Guidelines for Coordinated Outpatient Oral Anticoagulation Therapy Management , 1997, The Annals of pharmacotherapy.
[265] J. Hirsh,et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. , 1997, Blood.
[266] P. Andrews,et al. Comparison of the hemodynamic and hematologic toxicity of a protamine variant after reversal of low-molecular-weight heparin anticoagulation in a canine model. , 1997, Laboratory animal science.
[267] F. Rosendaal,et al. Emergency Oral Anticoagulant Reversal: The Relative Efficacy of Infusions of Fresh Frozen Plasma and Clotting Factor Concentrate on Correction of the Coagulopathy , 1997, Thrombosis and Haemostasis.
[268] A. Norman,et al. A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. , 1997, European journal of cancer.
[269] S. Booth,et al. Dietary Vitamin and Stability of Oral Anticoagulation: Proposal of a Diet with Constant Vitamin K1 Content , 1997, Thrombosis and Haemostasis.
[270] J. Hirsh,et al. Comparison of 5-mg and 10-mg Loading Doses in Initiation of Warfarin Therapy , 1997, Annals of Internal Medicine.
[271] T. Ortel,et al. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic Warfarin therapy , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[272] T. Ortel,et al. Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants , 1997, Annals of Internal Medicine.
[273] Kenneth J. Alford,et al. Novastan® (Brand of Argatroban): A Small-Molecule, Direct Thrombin Inhibitor , 1997, Seminars in thrombosis and hemostasis.
[274] R. Marlar,et al. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. , 1997, American journal of clinical pathology.
[275] O. Chazouilleres,et al. Prothrombin time in liver failure: Time, ratio, activity percentage, or international normalized ratio , 1996, Hepatology.
[276] J. Ansell,et al. Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. , 1996, American heart journal.
[277] W. J. Hamilton,et al. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.
[278] A. D’Angelo,et al. Potential failure of the International Normalized Ratio (INR) System in the monitoring of oral anticoagulation in patients with lupus anticoagulants. , 1996, Annales de medecine interne.
[279] D. Singer,et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. , 1996, The New England journal of medicine.
[280] Vittorio Pengo,et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) , 1996, The Lancet.
[281] J. Hirsh,et al. Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio. , 1996, The Journal of laboratory and clinical medicine.
[282] M. Lettino,et al. Biochemistry and biology of hirudin. , 1996, Coronary artery disease.
[283] S. Fihn,et al. The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin , 1996, Annals of Internal Medicine.
[284] M. Andrew,et al. Decreased Thrombin Activity of Fibrin Clots Prepared in Cord Plasma Compared with Adult Plasma , 1996, Pediatric Research.
[285] David C. Anderson,et al. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. , 1996, Archives of internal medicine.
[286] R. Wallis,et al. Hirudins: From Leeches to Man , 1996, Seminars in thrombosis and hemostasis.
[287] J. Necciari,et al. Pharmacokinetics and Tolerance of the Natural Pentasaccharide (SR90107/ORG31540) with High Affinity to Antithrombin III in Man , 1995, Thrombosis and Haemostasis.
[288] R. Hall,et al. Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. , 1995, European heart journal.
[289] E. Mascha,et al. Accuracy of laboratory and portable monitor international normalized ratio determinations. Comparison with a criterion standard. , 1995, Archives of internal medicine.
[290] F. Violi,et al. Thrombosis in the antiphospholipid-antibody syndrome. , 1995, The New England journal of medicine.
[291] P. Maccallum,et al. Minidose Warfarin and Failure to Prevent Deep Vein Thrombosis After Joint Replacement Surgery Despite Inhibiting the Postoperative Rise in Plasminogen Activator Inhibitor Activity , 1995 .
[292] B. Gersh,et al. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. , 1995, Mayo Clinic proceedings.
[293] P. Koudstaal. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. , 1995, The New England journal of medicine.
[294] J. Vandenbroucke,et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. , 1995, The New England journal of medicine.
[295] P. Andrews,et al. Effective and less toxic reversal of low-molecular weight heparin anticoagulation by a designer variant of protamine. , 1995, Journal of vascular surgery.
[296] F. Fried,et al. Anticoagulant associated hematuria: a prospective study. , 1995, The Journal of urology.
[297] G. Hughes,et al. The management of thrombosis in the antiphospholipid-antibody syndrome. , 1995, The New England journal of medicine.
[298] M. Wolzt,et al. Studies on the Neutralizing Effects of Protamine on Unfractionated and Low Molecular Weight Heparin (Fragmin®) at the Site of Activation of the Coagulation System in Man , 1995, Thrombosis and Haemostasis.
[299] K. Denson,et al. Validity of the INR System for Patients with Liver Impairment , 1995, Thrombosis and Haemostasis.
[300] M. Beaudet,et al. Age-associated risks of prophylactic anticoagulation in the setting of hip fracture. , 1995, The American journal of medicine.
[301] E. Duncan,et al. Effect of Concentration of Trisodium Citrate Anticoagulant on Calculation of the International Normalised Ratio and the International Sensitivity Index of Thromboplastin , 1994, Thrombosis and Haemostasis.
[302] M. Beaudet,et al. Age-associated risks of prophylactic anticoagulation in the setting of hip fracture , 1994 .
[303] E. Hylek,et al. Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin , 1994, Annals of Internal Medicine.
[304] M. Kovacs,et al. Assessment of the Validity of the INR System for Patients with Liver Impairment , 1994, Thrombosis and Haemostasis.
[305] S. Rapaport,et al. The International Normalized Ratio (INR) for Monitoring Warfarin Therapy: Reliability and Relation to Other Monitoring Methods , 1994, Annals of Internal Medicine.
[306] T. Culclasure,et al. The significance of hematuria in the anticoagulated patient. , 1994, Archives of internal medicine.
[307] M. Pini,et al. A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol). , 1994, Thrombosis and haemostasis.
[308] H. White,et al. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : stroke prevention in atrial fibrillation II study. Commentary , 1994 .
[309] P. Mannucci,et al. Are Capillary Whole Blood Coagulation Monitors Suitable for the Control of Oral Anticoagulant Treatment by the International Normalized Ratio? , 1993, Thrombosis and Haemostasis.
[310] A. Zivelin,et al. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. , 1993, The Journal of clinical investigation.
[311] E. Garelli,et al. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[312] R. Beyth,et al. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. , 1993, The American journal of medicine.
[313] T. Pastoor,et al. Case management and plasma half-life in a case of brodifacoum poisoning. , 1993, Archives of internal medicine.
[314] A. Laupacis,et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. , 1993, The New England journal of medicine.
[315] C. Francis,et al. Comparison of Native Prothrombin Antigen With the Prothrombin Time for Monitoring Oral Anticoagulant Prophylaxis , 1993, Circulation.
[316] A. James,et al. Prospective comparative study of computer programs used for management of warfarin. , 1993, Journal of clinical pathology.
[317] E. Gottfried,et al. Failure of the International Normalized Ratio to generate consistent results within a local medical community. , 1993, American journal of clinical pathology.
[318] K. High,et al. Decentralized testing for prothrombin time and activated partial thromboplastin time using a dry chemistry portable analyzer. , 1993, Archives of pathology & laboratory medicine.
[319] Donald Martin,et al. Risk Factors for Complications of Chronic Anticoagulation: A Multicenter Study , 1993, Annals of Internal Medicine.
[320] T. Barbui,et al. Thrombotic and Hemorrhagic Complications in Patients with Mechanical Heart Valve Prosthesis Attending an Anticoagulation Clinic , 1993, Thrombosis and Haemostasis.
[321] F. Marongiu,et al. Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal. , 1993, Haemostasis.
[322] F R Rosendaal,et al. A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.
[323] J. Maraganore,et al. Anticoagulant Activity of Hirulog™, a Direct Thrombin Inhibitor, in Humans , 1993, Thrombosis and Haemostasis.
[324] P. Mannucci,et al. Status of Present and Candidate International Reference Preparations (IRP) of Thromboplastin for the Prothrombin Time , 1993, Thrombosis and Haemostasis.
[325] Leandro Provinciali,et al. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .
[326] D. Banner,et al. Inhibitor binding to thrombin: x-ray crystallographic studies. , 1993, Advances in experimental medicine and biology.
[327] J. Vandenbroucke,et al. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. , 1993, Archives of internal medicine.
[328] D. Mungall,et al. Aging and warfarin therapy. , 1992, Annals of internal medicine.
[329] S M Nazarian,et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.
[330] M. Rosove,et al. Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients , 1992, Annals of Internal Medicine.
[331] S. Thompson,et al. Factors affecting the maintenance dose of warfarin. , 1992, Journal of clinical pathology.
[332] J. Avorn,et al. Aging and the Anticoagulant Response to Warfarin Therapy , 1992, Annals of Internal Medicine.
[333] M. Sakon,et al. Bedside monitoring of warfarin therapy by a whole blood capillary coagulation monitor. , 1992, Thrombosis research.
[334] D L Kent,et al. A Model for Planning Optimal Follow-up for Outpatients on Warfarin Anticoagulation , 1992, Medical decision making : an international journal of the Society for Medical Decision Making.
[335] S. McCurdy,et al. Accuracy and precision of a portable anticoagulation monitor in a clinical setting. , 1992, Archives of internal medicine.
[336] P. Delmas,et al. Protein-S, a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblasts. , 1992, Endocrinology.
[337] D. P. Bentley,et al. Effective Reversal of Warfarin-lnduced Excessive Anticoagulation with Low Dose Mtamin K1 , 1992, Thrombosis and Haemostasis.
[338] J. C. Martin. Anaphylactoid reactions and vitamin K , 1991, The Medical journal of Australia.
[339] M. Dunn,et al. Low-intensity anticoagulation in mechanical cardiac prosthetic valves. , 1991, Chest.
[340] T. Baglin,et al. Evaluation of the Ciba Corning Biotrack 512 coagulation monitor for the control of oral anticoagulation. , 1991, Journal of clinical pathology.
[341] A. Tulinsky,et al. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. , 1991, Journal of molecular biology.
[342] M Gent,et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. , 1991, Journal of the American College of Cardiology.
[343] Lippincott Williams Wilkins,et al. Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.
[344] G. Staddon,et al. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. , 1991, BMJ.
[345] D. Howie,et al. Prevention of venous thrombosis with minidose warfarin after joint replacement. , 1991, BMJ.
[346] B. Bain,et al. The association of age with dosage requirement for warfarin. , 1991, Age and ageing.
[347] J. Heaf,et al. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients , 1991, Journal of internal medicine.
[348] E. Gurfinkel,et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. , 1991, The Journal of thoracic and cardiovascular surgery.
[349] A. Berstad,et al. Incomplete reversal of enoxaparin-induced bleeding by protamine sulfate. , 1991, Haemostasis.
[350] G. Houin,et al. Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. , 1991, Nephron.
[351] M. Kazama,et al. Evaluation of International Normalized Ratios by a Controlled Field Survey with 4 Different Thromboplastin Reagents , 1990, Thrombosis and Haemostasis.
[352] Bernard Rosner,et al. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.
[353] D. Massel,et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.
[354] L. Poller,et al. Automation and prothrombin time: a United Kingdom field study of two widely used coagulometers. , 1990, Journal of clinical pathology.
[355] J. Maraganore,et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. , 1990, Biochemistry.
[356] P Smith,et al. The effect of warfarin on mortality and reinfarction after myocardial infarction. , 1990, The New England journal of medicine.
[357] D. Bergqvist,et al. Effects of Low Molecular Weight Heparin and Unfragmented Heparin on Induction of Osteoporosis in Rats , 1990, Thrombosis and Haemostasis.
[358] M. Ray,et al. The Dependence of the International Sensitivity Index on the Coagulometer Used to Perform the Prothrombin Time , 1990, Thrombosis and Haemostasis.
[359] J. Hirsh,et al. Neutralization of Enoxaparine-lnduced Bleeding by Protamine Sulfate , 1990, Thrombosis and Haemostasis.
[360] P. Benotti,et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. , 1990, Annals of internal medicine.
[361] A. Gallus,et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. , 1990, The New England journal of medicine.
[362] B. Furie,et al. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. , 1990, Blood.
[363] M. Monreal,et al. Heparin-related osteoporosis in rats. A comparative study between unfractioned heparin and a low-molecular-weight heparin. , 1990, Haemostasis.
[364] A. James,et al. Computer control of anticoagulant dose , 1989, BMJ.
[365] R. Weibert,et al. Evaluation of a capillary whole-blood prothrombin time measurement system. , 1989, Clinical pharmacy.
[366] E. van der Velde,et al. The Effect of Some Instruments for Prothrombin Time Testing on the International Sensitivity Index (ISI) of Two Rabbit Tissue Thromboplastin Reagents , 1989, Thrombosis and Haemostasis.
[367] P. J. Ryan,et al. Computer control of anticoagulant dose for therapeutic management. , 1989, BMJ.
[368] S A McCurdy,et al. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study. , 1989, Annals of internal medicine.
[369] P. Bonini,et al. Comparison of two automated coagulometers and the manual tilt-tube method for the determination of prothrombin time. , 1989, American journal of clinical pathology.
[370] L Goldman,et al. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. , 1989, The American journal of medicine.
[371] L Goldman,et al. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. , 1989, The American journal of medicine.
[372] G. Clark,et al. The Safety and Effectiveness of Long‐Term Warfarin Therapy in an Anticoagulation Clinic , 1989, Pharmacotherapy.
[373] J B Lian,et al. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. , 1989, Physiological reviews.
[374] N. A. Schmidt,et al. Correction of instrument- and reagent-based differences in determination of the International Normalized Ratio (INR) for monitoring anticoagulant therapy. , 1989, Clinical chemistry.
[375] M. Klauber,et al. Effect of erythromycin in patients receiving long-term warfarin therapy. , 1989, Clinical pharmacy.
[376] S. Schulman,et al. Interaction of ibuprofen and warfarin on primary haemostasis. , 1989, British Journal of Rheumatology.
[377] Palle Petersen,et al. PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.
[378] E. Kruithof,et al. Necrosis of skin induced by coumarin in a patient deficient in protein S. , 1989, BMJ.
[379] L. Poller,et al. Effect of automation on prothrombin time test in NEQAS surveys. , 1989, Journal of clinical pathology.
[380] A. Bayer,et al. Can old people on oral anticoagulants be safely managed as out-patients? , 1988, Postgraduate medical journal.
[381] M. Rhee,et al. Normal and warfarin-resistant rat hepatocyte metabolism of vitamin K 2,3-epoxide: evidence for multiple pathways of hydroxyvitamin K formation. , 1988, Archives of biochemistry and biophysics.
[382] J. Hirsh,et al. RANDOMISED COMPARISON OF TWO INTENSITIES OF ORAL ANTICOAGULANT THERAPY AFTER TISSUE HEART VALVE REPLACEMENT , 1988, The Lancet.
[383] W. Hauser,et al. Complications of long‐term anticoagulation , 1988, Annals of neurology.
[384] C. Wilcox,et al. Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy. , 1988, The American journal of medicine.
[385] M. Israel. Significance of occult gastrointestinal bleeding during anticoagulation therapy , 1988 .
[386] B. Lyle,et al. Vitamin K deficiency from dietary vitamin K restriction in humans. , 1988, The American journal of clinical nutrition.
[387] V. Fuster,et al. Anticoagulation clinics and the monitoring of anticoagulant therapy. , 1988, International journal of cardiology.
[388] P. Price. Role of vitamin-K-dependent proteins in bone metabolism. , 1988, Annual review of nutrition.
[389] L. S. Wickramasinghe,et al. Long-term oral anticoagulant therapy in elderly patients. , 1988, Age and ageing.
[390] A. Breckenridge,et al. The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. , 1988, British journal of clinical pharmacology.
[391] D. Atha,et al. Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. , 1987, Biochemistry.
[392] D. Mungall,et al. A novel whole blood capillary technic for measuring the prothrombin time. , 1987, American journal of clinical pathology.
[393] T. Wakefield,et al. Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors. , 1987, Thrombosis research.
[394] W. Trager,et al. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans , 1987, Clinical pharmacology and therapeutics.
[395] L. Poller. Laboratory control of oral anticoagulants. , 1987, British medical journal.
[396] G. Schuster,et al. Clinical significance of hematuria in patients on anticoagulant therapy. , 1987, The Journal of urology.
[397] G. Mcinnes,et al. The Performance of Clinics for Out-Patient Control of Anticoagulation , 1987, Journal of the Royal College of Physicians of London.
[398] R. O'Reilly,et al. Warfarin metabolism and drug-drug interactions. , 1987, Advances in experimental medicine and biology.
[399] B. Furie,et al. Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid. Conformation-specific antibodies directed against the phospholipid-binding site on prothrombin. , 1986, The Journal of biological chemistry.
[400] D. Petitti,et al. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. , 1986, The American journal of medicine.
[401] N. Zauber,et al. Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. , 1986, Annals of internal medicine.
[402] M. Gibaldi,et al. The warfarin‐sulfinpyrazone interaction: stereochemical considerations , 1986, Clinical pharmacology and therapeutics.
[403] A. Carpentier,et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. , 1986, Haemostasis.
[404] P. Price,et al. Sequence of the precursor to rat bone gamma-carboxyglutamic acid protein that accumulates in warfarin-treated osteosarcoma cells. , 1985, The Journal of biological chemistry.
[405] Lorentz Sm,et al. Potentiation of warfarin anticoagulation by topical testosterone ointment. , 1985 .
[406] J. Walenga,et al. Biochemical and Pharmacologic Studies on the Protamine Interactions with Heparin, Its Fractions and Fragments , 1985, Seminars in thrombosis and hemostasis.
[407] J. Choay. Biologic Studies on Chemically Synthesized Pentasaccharide and Tetrasaccharide Fragments , 1985, Seminars in thrombosis and hemostasis.
[408] K. Mann,et al. The kinetics of activation of normal and gamma-carboxyglutamic acid-deficient prothrombins. , 1985, The Journal of biological chemistry.
[409] D. Sackett,et al. The Ends of Human Life: Medical Ethics in a Liberal Polity , 1992, Annals of Internal Medicine.
[410] J. Ansell,et al. Management of oral anticoagulant therapy. Experience with an anticoagulation clinic. , 1984, Archives of internal medicine.
[411] John Anderson. Computer assisted management of warfarin treatment , 1984 .
[412] S. Gitel,et al. Warfarin. From bedside to bench. , 1984, The New England journal of medicine.
[413] E. Ritz,et al. Evidence for Impaired Hepatic Vitamin K1 Metabolism in Patients Treated with N-Methyl-Thiotetrazole Cephalosporins , 1984, Thrombosis and Haemostasis.
[414] J. Soria,et al. Successful Progressive Anticoagulation in a Severe Protein C Deficiency and Previous Skin Necrosis at the Initiation of Oral Anticoagulant Treatment , 1984, Thrombosis and Haemostasis.
[415] D. Skinner,et al. Warfarin necrosis of the skin and subcutaneous tissue of the male external genitalia. , 1983, The Journal of urology.
[416] R. Bertina,et al. Protein C and the Development of Skin Necrosis During Anticoagulant Therapy , 1983, Thrombosis and Haemostasis.
[417] T B Kirkwood,et al. Calibration of Reference Thromboplastins and Standardisation of the Prothrombin Time Ratio , 1983, Thrombosis and Haemostasis.
[418] V. Fuster,et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. , 1983, The American journal of cardiology.
[419] M. Weitekamp,et al. Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. , 1983, JAMA.
[420] G. Raskob,et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. , 1982, The New England journal of medicine.
[421] J. Suttie,et al. Evidence that warfarin anticoagulant action involves two distinct reductase activities. , 1982, The Journal of biological chemistry.
[422] J C Forfar,et al. Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio. , 1982, American heart journal.
[423] RISKS OF LONG-TERM ORAL ANTICOAGULANT THERAPY IN ELDERLY PATIENTS AFTER MYOCARDIAL INFARCTION Second Report of the Sixty Plus Reinfarction Study Research Group , 1982, The Lancet.
[424] T. Meinertz,et al. Pharmacokinetics of the enantiomers of acenocoumarol in man. , 1981, British journal of clinical pharmacology.
[425] R. O'Reilly. Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. , 1981, Archives of Internal Medicine.
[426] O'Reilly Ra,et al. "Resistance" to warfarin due to unrecognized vitamin K supplementation. , 1980 .
[427] E. Myhre,et al. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. , 1980, American heart journal.
[428] R. O'Reilly. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. , 1980, The New England journal of medicine.
[429] R. Pauli,et al. Maternal and fetal sequelae of anticoagulation during pregnancy. , 1980, The American journal of medicine.
[430] B. Rothschild. Hematologic perturbations associated with salicylate , 1979, Clinical pharmacology and therapeutics.
[431] J. Kelly,et al. Clinical Pharmacokinetics of Oral Anticoagulants , 1979, Clinical pharmacokinetics.
[432] J. Suttie,et al. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. , 1978, Biochemistry.
[433] P. Kubisz,et al. Inhibition of ADP-Induced Reptilase Clot Retraction by Specific Antibodies , 1978, Thrombosis and Haemostasis.
[434] A. Breckenridge. Oral anticoagulant drugs: pharmacokinetic aspects. , 1978, Seminars in hematology (Print).
[435] R. Rosenberg,et al. A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients. , 1977, Biochimica et biophysica acta.
[436] K. Mann,et al. Differentiation of metal ion-induced transitions of prothrombin fragment 1. , 1977, The Journal of biological chemistry.
[437] F. Davis,et al. Management of anticoagulation in outpatients: experience with an anticoagulation service in a municipal hospital setting. , 1977, Archives of internal medicine.
[438] A. Breckenridge,et al. Enantiomers of warfarin and phenobarbital. , 1976, The New England journal of medicine.
[439] G. Nelsestuen. Role of gamma-carboxyglutamic acid. An unusual protein transition required for the calcium-dependent binding of prothrombin to phospholipid. , 1976, The Journal of biological chemistry.
[440] R. O'Reilly. The stereoselective interaction of warfarin and metronidazole in man. , 1976, The New England journal of medicine.
[441] R. O'reilly,et al. Vitamin K and the oral anticoagulant drugs. , 1976, Annual Review of Medicine.
[442] P. Majerus,et al. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. , 1975, The Journal of clinical investigation.
[443] J. Pettifor,et al. Congenital malformations associated with the administration of oral anticoagulants during pregnancy. , 1975, The Journal of pediatrics.
[444] J. Howard,et al. The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. , 1974, The Journal of biological chemistry.
[445] C. Alfrey,et al. The hemostatic defect produced by carbenicillin. , 1974, The New England journal of medicine.
[446] R. Reilly. Studies on the optical enantiomorphs of warfarin in man , 1974 .
[447] P. Fernlund,et al. Vitamin K dependent modifications of glutamic acid residues in prothrombin. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[448] B. Vidne,et al. A self control method for long term anticoagulation therapy. , 1974, The Journal of cardiovascular surgery.
[449] A. Breckenridge,et al. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. , 1974, The Journal of clinical investigation.
[450] A. Breckenridge,et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man , 1974, Clinical pharmacology and therapy.
[451] A. Zimmermann,et al. Biochemical basis of hereditary resistance to warfarin in the rat. , 1974, Biochemical pharmacology.
[452] P. W. Willis,et al. Hemorrhagic complications of anticoagulant therapy. , 1974, Archives of internal medicine.
[453] J. Cazenave,et al. Effects of Penicillin G on Platelet Aggregation, Release, and Adherence to Collagen 1 , 1973, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[454] O'Reilly Ra,et al. Studies on the interaction of warfarin and clofibrate in man. , 1972 .
[455] P M Aggeler,et al. Studies on Coumarin Anticoagulant Drugs: Initiation of Warfarin Therapy Without a Loading Dose , 1968, Circulation.
[456] J. Udall. Human sources and absorption of vitamin K in relation to anticoagulation stability. , 1965, JAMA.
[457] J. C. Owens,et al. Effect of sodium dextrothyroxine in patients receiving anticoagulants. , 1962, The New England journal of medicine.
[458] A. Schirger,et al. Small doses of vitamin K1 for correction of reduced prothrombin activity. , 1959, Proceedings of the staff meetings. Mayo Clinic.
[459] S. Cosgriff. The effectiveness of an oral vitamin K1 in controlling excessive hypoprothrombinemia during anticoagulant therapy. , 1956, Annals of internal medicine.
[460] R. K. Richards. INFLUENCE OF FEVER UPON THE ACTION OF 3,3'-METHYLENE-BIS-(4-HYDROXYCOUMARIN) (DICUMAROL). , 1943, Science.